Boston Scientific Corporation
BSX reports clinical endpoint data from the PLATINUM Long Lesion
trial, demonstrating positive outcomes for the PROMUS Element™
Everolimus-Eluting Platinum Chromium (PtCr) Stent System in patients with long
coronary lesions. Results were presented today by Paul S. Teirstein, M.D., of
the Scripps Clinic in La Jolla, California, and Co-Principal Investigator of
the trial, at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT)
scientific symposium, sponsored by the Cardiovascular Research Foundation.
"The PROMUS Element Stent achieved impressive clinical outcomes in this
patient population with long lesions," said Dr. Teirstein. "This durable
polymer everolimus-based stent, built on the advanced platinum chromium
platform, demonstrated low rates of revascularization while reporting no
myocardial infarction or stent thrombosis at two years, and should offer
physicians confidence and flexibility in treating longer lesions with a single
stent."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in